Birkel v. Gheith: Punitives Carry the Number
A St. Louis County jury handed Patricia Birkel a $37.04M verdict on Aug. 25, 2026, against Dr. Gheith and Interventional Pain Institute, with coverage surfacing widely on Nov. 4. The compensatory component was $7.04M; punitives made up the remainder, $20M against the physician and $10M against the clinic.
The theory was delay, not technique: counsel established that worsening neurological symptoms should have triggered a thoracic MRI well before the spinal mass was found, and that the delay produced irreversible tissue degeneration and partial paralysis. Defense has filed to stay judgment pending appeal, a near-certain move given the punitive ratio.
For case managers, the file is a template for documenting symptom-escalation timelines against ordering decisions. Jurors rewarded a clean causal chain from missed imaging to permanent deficit, not a battle of competing standard-of-care experts.
Firms litigating delayed-diagnosis spine cases should pull Birkel's symptom-timeline exhibits as a drafting model before their next mediation.
FDA Recalls Turn Into Immediate Facility Exposure
The FDA's Nov. 2 early alert on three lots of B. Braun's Streamline Bloodline Set for the Dialog+ hemodialysis system flags a connector that may detach or leak during priming or treatment, with risk of blood loss, clotting, or air embolism. Dialysis centers and hospitals that keep using recalled lots after notice face direct negligence exposure, separate from any manufacturer claim.
Two device recalls from earlier this fall remain active intake targets. Medtronic's Bravo esophageal pH capsule delivery device carries a Class I classification from Sept. 15, with Medtronic itself reporting 184 serious injuries tied to the recall. Boston Scientific's spinal cord stimulator lead recall, flagged Sept. 3, keeps implanting surgeons and spine-surgery centers both in the exposure chain.
Counsel screening new SCS or Bravo-related intakes should separate delivery-device failure theories from device-design claims early, since the forum and expert pool differ materially between the two.
Any facility still running recalled B. Braun bloodline lots after Nov. 2 has converted a manufacturer problem into its own negligence file.
Failure-to-Disclose: A $7.5M Result Without a Scalpel
A New Jersey jury awarded $7.5M to a Kasowitz partner on Nov. 3 after a physician failed to disclose that a diagnostic test had already shown lung cancer. No surgical error, no device, no delay in ordering the test itself; the breach was communication of a result already in hand.
The verdict sits at policy-limits territory for many community carriers and should recalibrate how firms screen informed-consent and results-disclosure intakes. These cases often get passed over for flashier surgical-error files, but the liability theory is simpler to prove and the damages model scales the same way.
Paralegals building intake checklists should add a standing question: did the patient's own records show the finding before anyone told them.
Failure-to-disclose claims are proving as valuable as surgical-error cases while requiring a thinner expert file.
Georgia Keeps Multi-Provider Liability From Splitting Away
On Oct. 16 the Georgia Court of Appeals affirmed a trial court's refusal to let a surgeon shift liability share to a co-defendant physician in a $6.8M med-mal settlement out of Fulton County. The ruling reaffirms Georgia's indivisibility doctrine in multi-provider injury cases, protecting the plaintiff's recovery from a late-stage apportionment fight between defendants.
That matters in facility-plus-physician cases, where defense counsel frequently try to carve fault between the treating doctor and the hospital or surgery center after settlement terms are already on the table. Georgia's appellate court closed that door again.
Firms with pending Fulton County or similar Georgia multi-defendant files should cite this ruling early in settlement negotiations rather than waiting for a post-settlement allocation dispute to force the issue.
Georgia plaintiffs' counsel now have fresh appellate cover against late apportionment maneuvers between co-defendants.
Liens and Reimbursement: What Providers Need to Flag Now
The Daily Journal's Sept. 4 warning on self-funded ERISA plans remains the operational headline for both counsel and lien-based medical providers this quarter: self-funded employer plans are increasingly refusing to reduce subrogation claims in PI settlements, and ERISA preemption limits the state-court equitable-reduction arguments firms have relied on for years.
Providers billing on a lien should flag ERISA-plan payers at intake, not at settlement. Firms building case value need to budget extended lien-resolution time once an ERISA plan is identified, since negotiation leverage is weaker than with Medicare or Medicaid liens.
California providers face a parallel tightening. SB 623, effective Jan. 1, 2027, layers a 70th-percentile FAIR Health cap onto TNC claims, and judges citing that benchmark are expected to scrutinize lien-doctor billing more aggressively starting Q1 2027, with likely spillover into non-TNC files. MICRA's non-economic cap rose to $470,000 on Jan. 1, 2026, prompting California facility defendants to raise settlement reserves.
Lien-directory listings that document billing methodology against FAIR Health percentiles, rather than relying on Pebley's full-billed-amount presumption alone, will hold up better once SB 623 scrutiny reaches non-TNC cases.
Providers and firms that haven't yet tagged ERISA-plan payers and FAIR Health benchmarks in their intake workflow are building settlement reserves on outdated assumptions.
Expert Vetting: A Missouri Retrial Warning
A Missouri court ordered a new med-mal trial in November coverage after finding a plaintiff's expert had an undisclosed history of advocacy in prior tort suits. The ruling is a reminder that Daubert and Frye vetting isn't a defense-side exercise alone.
Plaintiff firms retaining repeat experts across multiple tort practice areas should run a conflict and disclosure check before designation, not after opposing counsel does it for them. A retrial order erases months of trial preparation and can reset damages leverage entirely.
Case managers tracking expert rosters across active files should cross-reference prior testimony history whenever the same expert appears in more than one pending matter.
One undisclosed advocacy history cost a plaintiff team its verdict and forced a full retrial.